When.com Web Search

  1. Ads

    related to: er pr her2 negative prognosis life expectancy chart by year

Search results

  1. Results From The WOW.Com Content Network
  2. Breast cancer classification - Wikipedia

    en.wikipedia.org/wiki/Breast_cancer_classification

    Breast cancer cells may or may not have many different types of receptors, the three most important in the present classification being: estrogen receptor (ER), progesterone receptor (PR), and HER2/neu. Cells with or without these receptors are called ER positive (ER+), ER negative (ER-), PR positive (PR+), PR negative (PR-), HER2 positive ...

  3. Hormone receptor positive breast tumor - Wikipedia

    en.wikipedia.org/wiki/Hormone_receptor_positive...

    ER-positive is one of the Receptor statuses identified in the classification of breast cancer.Receptor status was traditionally considered by reviewing each individual receptor (ER, PR, her2) in turn, but newer approaches look at these together, along with the tumor grade, to categorize breast cancer into several conceptual molecular classes [1] that have different prognoses [2] and may have ...

  4. Triple-negative breast cancer - Wikipedia

    en.wikipedia.org/wiki/Triple-negative_breast_cancer

    Triple-negative breast cancer (TNBC) is any breast cancer that either lacks or shows low levels of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) overexpression and/or gene amplification (i.e. the tumor is negative on all three tests giving the name triple-negative). [1]

  5. Breast cancer - Wikipedia

    en.wikipedia.org/wiki/Breast_cancer

    The five-year survival rates in England and the United States are between 80 and 90%. [16] [4] [5] In developing countries, five-year survival rates are lower. [2] Worldwide, breast cancer is the leading type of cancer in women, accounting for 25% of all cases. [17] In 2018, it resulted in two million new cases and 627,000 deaths. [18]

  6. HER2 - Wikipedia

    en.wikipedia.org/wiki/HER2

    HER2 is the target of the monoclonal antibody trastuzumab (marketed as Herceptin). Trastuzumab is effective only in cancers where HER2 is over-expressed. One year of trastuzumab therapy is recommended for all patients with HER2-positive breast cancer who are also receiving chemotherapy. [33] Twelve months of trastuzumab therapy is optimal.

  7. IHME also analyzed the US’ health-adjusted life expectancy (HALE), which is the average number of years a person can expect to live in good health. The US’ HALE global ranking is forecast to ...

  1. Ads

    related to: er pr her2 negative prognosis life expectancy chart by year